• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KORU Medical Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    4/4/25 4:03:11 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care
    Get the next $KRMD alert in real time by email
    Form 8-K
    false 0000704440 0000704440 2025-03-31 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported)   March 31, 2025

     

    KORU Medical Systems, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 0-12305 13-3044880
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

     

    100 Corporate Drive, Mahwah, NJ 07430
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code   (845) 469-2042

     

    ______________________________________________

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    [_]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    [_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    [_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    [_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading symbol(s) Name of each exchange on which registered
    common stock, $0.01 par value KRMD The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  [_]

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

     


     

    ITEM 1.01   ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

     

    On March 31, 2025, KORU Medical Systems, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its loan and security agreement, by and between the Company and HSBC Ventures USA Inc., as lender, dated March 8, 2024 (the “Loan and Security Agreement”). The Company has not drawn on the credit facility under the Loan and Security Agreement, and there is no obligation for the Company to do so at any time.

     

    The Amendment extends the maturity of the $5,000,000 revolving credit facility to December 31, 2026, and extends the interest-only portion of the $5,000,000 term loan facility to October 1, 2026. The Amendment also changes the Adjusted Quick Ratio from not less than 1.50 to 1.00, to not less than 1.25 to 1.00.

     

    The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated by reference into this Item 1.01.

     

    ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

     

    Exhibits.

     

    Exhibit No.   Description
         
    10.1+   Amendment No. 1 to Loan and Security Agreement dated as of March 31, 2025 by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc.
         
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    + Schedules and exhibits have been omitted pursuant to Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request.

     

    - 2 -


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      KORU Medical Systems, Inc.
    (Registrant)
         
    Date:  April 4, 2025 By: /s/ Linda Tharby
      Linda Tharby
    President and Chief Executive Officer

     

    - 3 -


    Get the next $KRMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KRMD

    DatePrice TargetRatingAnalyst
    2/14/2025$4.50Overweight → Neutral
    Piper Sandler
    7/25/2024$4.00Buy
    B. Riley Securities
    9/7/2023$4.00Buy
    Lake Street
    9/7/2023$4.50Buy
    B. Riley Securities
    11/10/2022$3.00 → $4.00Hold → Buy
    Canaccord Genuity
    11/10/2022$3.00 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $KRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cascella Robert was granted 4,189 shares, increasing direct ownership by 5% to 84,615 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      7/2/25 5:17:08 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Director Wholihan Edward was granted 4,189 shares, increasing direct ownership by 12% to 37,772 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      7/2/25 4:56:36 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Director Matin Shahriar was granted 4,189 shares, increasing direct ownership by 5% to 87,604 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      7/2/25 4:55:10 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    SEC Filings

    See more
    • KORU Medical Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/15/25 4:56:41 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by KORU Medical Systems Inc.

      10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/7/25 4:22:04 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/7/25 4:21:14 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KORU Medical Systems downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50

      2/14/25 8:08:51 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on KORU Medical Systems with a new price target

      B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

      7/25/24 8:28:49 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on KORU Medical Systems with a new price target

      Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

      9/7/23 9:12:10 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Manko Joseph M. Jr. bought $349,999 worth of shares (145,833 units at $2.40) and sold $349,999 worth of shares (145,833 units at $2.40) (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      12/15/23 4:05:24 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

      7/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

      6/11/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio

      11/8/23 4:08:00 PM ET
      $BDX
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

      SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

      11/14/24 7:00:30 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

      SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

      11/13/24 4:23:54 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by KORU Medical Systems Inc.

      SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)

      5/23/24 7:00:28 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Financials

    Live finance-specific insights

    See more
    • KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2025 financial results on Wednesday, August 6, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internationa

      7/16/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

      5/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call

      4/16/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2025 financial results on Wednesday, August 6, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internationa

      7/16/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

      7/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

      6/11/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care